Biomarkers for memory decline after brain hemorrhage
Treatments studied
Part of Brain & nervous system clinical trials.
This study looks for biological signs that might predict memory problems after a brain bleed, which could help doctors provide better care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a brain bleed (intracerebral hemorrhage)
- You are between 18 and 79 years old
- You do not already have dementia
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for a simple blood test that might help predict how well people recover after a brain bleed (intracerebral hemorrhage). If you've recently had this type of bleeding, researchers want to see if certain markers in your blood can give clues about your outlook.
This study looks for markers in your blood and brain scans that may help doctors better understand and predict outcomes after a spontaneous brain bleed. It is for people with high blood pressure who have had a bleed within the last three days.
This study looks at whether blood tests taken after your first stroke can help predict if you might have memory or thinking problems early on. It focuses on people with a stroke in the basal ganglia area of the brain, with the goal of identifying those who may need extra support sooner.
This study is testing whether certain substances in your blood can help doctors better detect and understand problems with blood flow in the brain. Researchers hope these new 'biomarkers' could lead to faster and more accurate diagnosis of conditions like stroke and mini-stroke.
This study looks at two proteins in the blood that may be linked to brain swelling after a bleeding stroke (intracerebral hemorrhage). It aims to understand how the body's immune response affects recovery, which could lead to better treatments.
This study looks at blood and imaging markers (biomarkers) to better understand and diagnose dementia and mild cognitive impairment. It aims to improve early detection and may help guide future treatments.
Hear when a new Primary Intracerebral Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.